{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ONC",
  "name": "BeOne Medicines Ltd.",
  "url": "https://orbyd.app/dossiers/ONC/",
  "json_url": "https://orbyd.app/dossiers/ONC.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "BRUKINSA-driven oncology compounder: sell-side racing to catch up — six PT raises/upgrades Jul 1–23, avg PT ~$415 vs ~$326 spot — as the drug takes global BTK leadership and BeOne turns GAAP-profitable. The 2026-08-05 Q2 print is the near-term binary.",
  "invalidation_trigger": "A weekly close below $290 breaks the base built through the July upgrade cycle; secondary: BRUKINSA US growth decelerating toward the low-20s% YoY on the 2026-08-05 print, or the oncology-immunology theme rolling to SATURATED with no replacement catalyst.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings confirmed for 2026-08-05 BMO, 8:00 ET call — binary print, blackout window opens ~2026-07-31 (3 trading days prior).",
    "Formal interim results with US-GAAP-to-IFRS reconciliation due on/before 2026-08-31 (Swiss-domicile artifact).",
    "CNY446M (~$62M) China tax settlement to be booked in Q2 GAAP results — expect a one-time GAAP drag on the headline number.",
    "Redomicile complete: BeiGene → BeOne Medicines, ticker BGNE → ONC on Nasdaq.",
    "Spring 2026 52-wk high $385.22; watch for a reclaim attempt vs the $290 base-break level."
  ],
  "body_markdown": "## Current Thesis\nBeOne (formerly BeiGene, redomiciled to Switzerland, ticker moved BGNE → ONC) is the cleanest fundamental-momentum story in large-cap oncology right now. BRUKINSA (zanubrutinib) is winning the global BTK-inhibitor share war just as Imbruvica hits its 2026 US/EU patent cliff, and the company has crossed into sustained GAAP profitability. Sell-side is scrambling to reprice: six PT raises/upgrades between 2026-07-01 and 2026-07-23. Spot sits ~$326, roughly 15% below the $385 52-week high, consolidating while estimates ratchet higher. The 2026-08-05 Q2 print is the near-term binary that gates a fresh entry.\n\n## Bull Case\n- Q1 2026 (reported ~2026-05-06): total revenue $1.5B, +35% YoY; BRUKINSA $1.1B, +38% YoY — annualizing ~$4.4B against $1.3B of full-year 2023 zanubrutinib sales. GAAP diluted EPS/ADS $1.96, non-GAAP $3.24; the profitability inflection is showing in reported numbers.\n- FY2026 guidance raised to $6.3–6.5B on 2026-05-06, a $100M lift from the February $6.2–6.4B range.\n- Upgrade cluster confirms narrative acceleration: Jefferies upgrade to Buy PT $380 (7/13), JPM Overweight $425 (7/23), RBC Outperform $451 (7/7), Truist Buy $416 (7/7), Barclays Overweight $403 (7/14), Citizens Outperform $396 (7/1). Average PT ~$415 vs ~$326 spot ≈ 27% implied.\n- Phase 3 MANGROVE (2026-06-30): BRUKINSA + rituximab cut risk of progression or death 43% in frontline mantle-cell lymphoma, a label-expansion read ahead of planned filings that widens the franchise beyond CLL.\n- $300M New Jersey R&D/manufacturing expansion (2026-07-23) pushes total US manufacturing investment past $1B — an onshoring hedge against drug-tariff/IRA risk and a demand-confidence signal.\n- Imbruvica's primary US/EU patent expires in 2026; BRUKINSA and Calquence are the two share-takers as the incumbent rolls over.\n\n## Bear Case\n- The 2026-08-05 Q2 print is a live binary for anyone entering here; even a low-beta name (β 0.49) can gap on a soft guide.\n- China tax settlement of CNY446M (~$62M) is flagged to hit Q2 GAAP results (disclosed 2026-06-26) — a one-time drag that can muddy the headline GAAP number.\n- Calquence (AstraZeneca) is the other share-taker and was running near 64% of new-patient BTK starts in the US; the share war is unresolved, and any BRUKINSA US deceleration is the fundamental crack.\n- Valuation has caught up: ~$36B market cap, roughly 6x FY26 sales. The easy re-rate from \"unprofitable China biotech\" to \"profitable global oncology\" is largely spent; further upside needs earnings beats to carry it.\n- Price is ~15% off the $385 high, so spring momentum has cooled; a failed reclaim of that shelf leaves it range-bound.\n\n## Setup & Price Structure\n- Spot ~$325.90 (2026-07-24 close), after-hours $322.64. 52-week range $253.95–$385.22, placing it mid-to-upper range and not stretched at highs.\n- Beta 0.49 — this trades like an institutional compounder; expect grind, not vertical.\n- Consolidating below the $385 high while estimates rise reads as coiled, not blown-off. No peak-retail-sentiment signature and no averaging-down setup at current levels.\n- The sell-side PT band $380–451 sits entirely above spot; the tape is still digesting the July upgrade wave.\n\n## Catalyst Calendar (next 30 days)\n- 2026-08-05 (before market open): Q2 2026 financial results with an 8:00 a.m. ET call — the binary. Key reads: BRUKINSA US growth rate, any FY guide revision, and the CNY446M tax-settlement GAAP impact.\n- On or before 2026-08-31: formal interim results announcement carrying a US-GAAP-to-IFRS reconciliation (an artifact of the Swiss domicile).\n- Ongoing, no fixed date: BRUKINSA frontline-MCL regulatory filings following MANGROVE; pipeline progress on sonrotoclax (BCL2) and BGB-16673 (BTK degrader).\n\n## What Would Change Our Mind\n- A weekly close below $290 breaks the base built through the July upgrade cycle and signals the momentum leg has failed.\n- BRUKINSA US growth decelerating toward the low-20s% YoY on the 2026-08-05 print (share ceded to Calquence) breaks the fundamental leg.\n- The oncology-immunology theme rolling from ACCELERATING to SATURATED with no fresh label or pipeline catalyst to replace it.\n- FY2026 guidance cut or held flat despite the Q1 raise.\n\n## Correlation Notes\n- BTK-franchise comps: AstraZeneca (AZN, Calquence) as the direct rival; AbbVie/J&J (Imbruvica) as the declining incumbent — BRUKINSA's gains are largely their losses.\n- Tracks the large-cap oncology/immunology cohort and biotech beta (XBI/IBB), though β 0.49 dampens broad-market drawdown pass-through.\n- The Swiss redomicile (BeiGene → BeOne, BGNE → ONC) removed part of the China-ADR discount overhang; residual China policy/tax headline risk remains, as the CNY446M settlement shows.",
  "first_seen": "2026-07-26",
  "last_analyzed": "2026-07-26T11:03:24+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}